Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

Benzinga · 1d ago
Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.